Preferential drug program for patients within the federal project for control of cardiovascular diseases: implementation strategy, results and prospects

A serious barrier to the widespread practical implementation of evidence therapy for cardiovascular diseases is financial constraints, which exacerbate low patient complience and affect inequality in cardiovascular health indicators population, increasing morbidity and mortality. At the level of healthcare systems in different countries, drug provision is recognized as an effective tool for increasing patient adherence to treatment and improving clinical outcomes. The problematic article discusses the preferential drug program within the federal project for control of cardiovascular diseases. The key principles for forming priority groups, mechanisms and stages of program implementation are outlined. Monitoring the program’s effectiveness made it possible to identify reserves and prospects for its further strategic development.

1. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100-32. doi:10.1016/S0140-6736(24)00367-2.

2. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020;395(10226):795-808.

3. Mensah GA, Wei GS, Sorlie PD, et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. Circ Res. 2017;120(2):366-80. doi:10.1161/CIRCRESAHA.116.309115.

4. Shlyakhto EV, Zvartau NE, Villevalde SV, et al. Cardiovascular risk management system: prerequisites for developing, organization principles, target groups. Russian Journal of Cardiology. 2019;(11):69-82. (In Russ.) doi:10.15829/1560-4071-2019-11-69-82.

5. Soloveva AE, Yakovlev AN, Villevalde SV, et al. Prescription drug coverage in high cardiovascular risk patients as an important part of the national goals achievement. Bulletin of Roszdravnadzor. 2019;4:20-7. (In Russ.) doi:10.35576/article_5d651dbc201140.18252870.

6. Khatana SAM, Khatana SAM, Bhatla A, et al. Association of Medicaid Expansion With Cardiovascular Mortality. JAMA Cardiol. 2019;4(7):671-9. doi:10.1001/jamacardio.2019.1651.

7. Rapsomaniki E, Thuresson M, Yang E, et al. Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction. Eur Heart J Qual Care Clin Outcomes. 2016;2(3):172-83. doi:10.1093/ehjqcco/qcw004.

8. Ma TT, Wong ICK, Man KKC, et al. Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis. PLoS One. 2019;14(1): e0210988. doi:10.1371/journal.pone.0210988.

9. Pan E, Nielsen SJ, Mennander A, et al. Statins for secondary prevention and major adverse events after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2022;164(6): 1875-86.e4. doi:10.1016/j.jtcvs.2021.08.088.

10. Simon ST, Kini V, Levy AE, Ho PM. Medication adherence in cardiovascular medicine. BMJ. 2021;374: n1493. doi:10.1136/bmj.n1493.

11. Allen NB, Holford TR, Bracken MB, et al. Trends in one-year recurrent ischemic stroke among the elderly in the USA: 1994-2002. Cerebrovasc Dis. 2010;30:525-32.

12. Hillen T, Coshall C, Tilling K, et al. Cause of stroke recurrence is multi-factorial: patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register. Stroke. 2003;34:1457-63.

13. Weintraub WS, Grau-Sepulveda MV, Weiss JM, et al. Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. Circulation. 2012;125(12):1501-10. doi:10.1161/CIRCULATIONAHA.111.066969.

14. Lewinter C, Bland JM, Crouch S, et al. Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: an analysis of 1706 patients. Eur J Heart Fail. 2014;16(1):95-102.

15. Pietrzykowski Ł, Michalski P, Kosobucka A, et al. Medication adherence and its determinants in patients after myocardial infarction. Sci Rep. 2020;10(1):12028.

16. Bansilal S, Castellano JM, Garrido E, et al. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes. J Am Coll Cardiol. 2016;68(8):789-801. doi:10.1016/j.jacc.2016.06.005.

17. Kulik A, Desai NR, Shrank WH, et al. Full prescription coverage versus usual prescription coverage after coronary artery bypass graft surgery: analysis from the post-myocardial infarction free Rx event and economic evaluation (FREEE) randomized trial. Circulation. 2013;128(11 Suppl 1): S219-25.

18. Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14. (In Russ.) doi:10.18087/cardio.2021.4.n1628.

19. Arutyunov AG, Dragunov DO, Arutyunov GP, et al. First Open Study of Syndrome of Acute Decompensation of Heart Failure and Concomitant Diseases in Russian Federation: Independent Registry ORAKUL. Kardiologiia. 2015;55(5):12-21. (In Russ.)

20. Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2022;10(2):73-84. doi:10.1016/j.jchf.2021.09.004.

21. Shlyakhto EV, Zvartau NE, Villevalde SV, et al. Implemented models and elements for heart failure care in the regions of the Russian Federation: prospects for transformation into regional cardiovascular risk management systems. Russian Journal of Cardiology. 2020;25(4):3792. (In Russ.) doi:10.15829/1560-4071-2020-4-3792.

22. Reitblat OM, Airapetian AA, Lazareva NV, et al. Creation of registers as one of the mechanisms for improving medical care for patients with chronic heart failure. Problem state. Terapevticheskii arkhiv. 2023;95(9):739-45. (In Russ.) doi:10.26442/00403660.2023.09.202370.

23. Boytsov SA, Blankova ZN, Svirida ON, et al. The first results of advanced medical care for chronic heart failure in different regions of the Russian Federation. Part I. Organization of care for chronic heart failure and prevalence of disease with reduced and preserved left ventricular ejection fraction. Russian Cardiology Bulletin. 2023;18(2):19-28. (In Russ.) doi:10.17116/Cardiobulletin20231802119.

24. Shlyakhto EV, Belenkov YuN, Boytsov SA, et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation "PRIORITET-CHF": initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):5593. (In Russ.) doi:10.15829/1560-4071-2023-5593.

25. Lam CSP, Gamble GD, Ling LH, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. Eur Heart J. 2018;39(20):1770-80. doi:10.1093/eurheartj/ehy005.

26. Narins CR, Aktas MK, Chen AY, et al. Arrhythmic and Mortality Outcomes Among Ischemic Versus Nonischemic Cardiomyopathy Patients Receiving Primary ICD Therapy. JACC Clin Electrophysiol. 2022;8(1):1-11. doi:10.1016/j.jacep.2021.06.020.

27. Loukianov MM, Martsevich SYu, Andrenko EYu, et al. Combination of Atrial Fibrillation and Coronary Heart Disease in Patients in Clinical Practice: Comorbidities, Pharmacotherapy and Outcomes (Data from the REСVASA Registries). Rational Pharmacotherapy in Cardiology. 2021;17(5):702-11. (In Russ.) doi:10.20996/1819-6446-2021-10-03.

28. Shlyakho EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801. (In Russ.) doi:10.15829/1560-4071-2020-3-3801.

29. Sayutina EV, Osadchuk MA, Romanov BK, et al. Cardiac rehabilitation and secondary prevention after acute myocardial infarction: a modern view on the problem. Rossiiskii meditsinskii zhurnal (Medical Journal of the Russian Federation, Russian Journal). 2021;27(6):571-87. (In Russ.) doi:10.17816/0869-2106-2021-27-6-571-587.

30. Villevalde SV, Zvartau NE, Yakovlev AN, et al. Association of medical staffing and out-comes in cardiovascular diseases. Russian Journal of Cardiology. 2020;25(4S):4236. (In Russ.) doi:10.15829/1560-4071-2020-4236.

31. Bockeria LA, Sokolskaya MA, Shvartz VA. Modern tendencies in the use of information and telecommunication technologies in the treatment of patients with cardiovascular diseases. Clinical Medicine (Russian Journal). 2020;98(9-10):656-64. (In Russ.) doi:10.30629/0023-2149-2020-98-9-10-656-664.